New 5-Drug cocktail aims to tackle High-Risk myeloma

NCT ID NCT07600151

Not yet recruiting Disease control Sponsor: Universitätsklinikum Hamburg-Eppendorf Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new five-drug combination for people newly diagnosed with a high-risk form of multiple myeloma. The drugs include etentamig, isatuximab, bortezomib, lenalidomide, and dexamethasone. The trial will enroll 220 participants and first check safety, then see if the treatment can make cancer undetectable at a deep level. It is an early-stage study, so the results will show whether this approach is promising enough for larger trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: etentamig, isatuximab, bortezomib, lenalidomide, and dexamethasone
What this could lead to: If successful, this could offer a more effective initial treatment for high-risk multiple myeloma, potentially leading to longer remission and survival.
What could go wrong: This is an early phase 1/2 trial, so safety and effectiveness are not yet proven. The five-drug combination may cause significant side effects, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELOMA MYELOMA MULTIPLE

Contacts and locations

Locations

University Medical Center Hamburg-Eppendorf

Hamburg, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.